ANGLE (LON:AGL) CEO Andrew Newlands is confident that his company will receive regulatory clearance for its innovative Parsortix cancer test by the third quarter 2020 following a successful meeting with the US Food and Drug Administration (FDA).
Newlands explains why that meeting was particularly important and how gratifying it was to see ANGLE catching the eye of significant investors at the recent JP Morgan Healthcare Conference in San Francisco.
Parsortix is a blood test designed to help doctors detect signs of cancer at an early stage, offering a less invasive alternative to tissue biopsies currently used in hospitals.
ANGLE said it is aiming to file its De Novo submission in the first quarter of 2020, with the prospect of regulatory clearance by the third quarter.
